Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>DexCom, Inc. reported its first-quarter 2025 earnings, demonstrating a commendable 14% organic revenue growth from the previous year.</li><li>The U.S. market drove much of this growth, achieving a 15% increase in revenue, fueled by robust demand and broader access to their continuous glucose monitoring (CGM) systems.</li><li>DexCom's strategic focus on expanding their prescriber base and enhancing commercial reach has begun to manifest in increased customer acquisition, particularly in the type 2 diabetes sector, where their coverage has expanded significantly.</li></ul>

DexCom, Inc. reported its first-quarter 2025 earnings, demonstrating a commendable 14% organic revenue growth from the previous year.The U.S. market drove much of this growth, achieving a 15% increase in revenue, fueled by robust demand and broader access to their continuous glucose monitoring (CGM) systems.DexCom's strategic focus on expanding their prescriber base and enhancing commercial reach has begun to manifest in increased customer acquisition, particularly in the type 2 diabetes sector, where their coverage has expanded significantly.

DexCom：インスリン非依存型 2 型糖尿病市場への浸透は画期的な動きとなるか？

Dexcom Inc

DexCom：インスリン非依存型 2 型糖尿病市場への浸透は画期的な動きとなるか？